PhaseRx, Inc. (NASDAQ:PZRX) Files An 8-K Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 5.03
|
Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year. |
To the extent applicable, the information set forth below under
Item 8.01 is incorporated herein by reference.
| Item 5.08 | Shareholder Director Nominations. |
To the extent applicable, the information set forth below under
Item8.01 is incorporated herein by reference.
| Item 8.01. | Other Events. |
On March6, 2017, the board of directors of PhaseRx, Inc. (the
Company) set the date of the Companys 2017 Annual Meeting of
Stockholders as Thursday, May25, 2017, at 8:00 a.m. Pacific Time,
at the office of the Company, located at 410 W. Harrison Street,
Suite 300, Seattle, Washington 98119 (the 2017Annual Meeting).
Stockholders of record as of the close of business on March31,
2017 will be entitled to notice of, and to vote at, the 2017
Annual Meeting.
The 2017 Annual Meeting is the Companys first annual meeting as a
public company. The Company has set a deadline for the receipt of
any stockholder proposals submitted to Rule14a-8 under the
Securities Exchange Act of 1934, as amended (the Exchange Act),
for inclusion in the Companys proxy materials for the 2017 Annual
Meeting as March31,2017, which the Company believes is a
reasonable time before it begins to print and distribute its
proxy materials. In order to be considered timely, such
stockholder proposals must be received by the Companys Corporate
Secretary at the address set forth below on or before the close
of business on March31, 2017 and comply with the procedures and
requirements set forth in Rule 14a-8 under the Exchange Act and
any applicable requirements of the Companys Amended and Restated
Bylaws.
A stockholder intending to submit a proposal outside the
processes of Rule 14a-8 or to nominate persons for election to
serve as a director of the Company, in each case in connection
with the 2017 Annual Meeting must provide written notice of such
proposal or nomination in accordance with the requirements set
forth in the Companys Amended and Restated Bylaws. To be
considered timely, any such notice must be received by the
Companys Corporate Secretary not later than March 31, 2017.
All stockholder proposals submitted to Rule 14a-8 under the
Exchange Act and all notices of other items of business or
director nominations to be brought before the 2017 Annual Meeting
must be directed to the Corporate Secretary, PhaseRx, Inc., 410
W. Harrison Street, Suite 300, Seattle, WA 98119.
About PhaseRx, Inc. (NASDAQ:PZRX)
PhaseRx, Inc is a biopharmaceutical company developing a portfolio of mRNA products to correct life-threatening inherited liver diseases in children. The Company’s initial product development focus is on urea cycle disorders, a group of rare genetic diseases that generally present before the age of 12 and are characterized by the body’s inability to remove ammonia from the blood. The Company’s i-ERT approach is enabled by its Hybrid mRNA Technology platform and is applicable to a number of inherited liver diseases. The Company is headquartered in Seattle. PhaseRx, Inc. (NASDAQ:PZRX) Recent Trading Information
PhaseRx, Inc. (NASDAQ:PZRX) closed its last trading session down -0.07 at 1.60 with 28,546 shares trading hands.
